Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation

被引:28
|
作者
Huang, Cindy [1 ]
Siu, Michele [1 ]
Vu, Lily [1 ]
Wong, Soo [1 ]
Shin, Jaekyu [1 ]
机构
[1] Univ Calif San Francisco, Dept Clin Pharm, Sch Pharm, San Francisco, CA 94143 USA
关键词
dabigatran; oral anticoagulants; physician behaviour; prescribing decision; prescription; warfarin; COST-EFFECTIVENESS; STROKE PREVENTION; WARFARIN; MEDICINES; PRESCRIBE; DECISION; CARE;
D O I
10.1111/j.1365-2753.2012.01886.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Rationale, aims and objectivesThis study was designed to examine the factors that influence doctors' decision in initiating or switching from warfarin to dabigratran. MethodA survey questionnaire was sent to 181 doctors who were most likely to prescribe dabigatran (e.g. cardiologists and general internists) at the University of California, San Francisco Medical Center between November 2011 and February 2012. Survey participants were asked to complete an electronic or a paper version of the questionnaire, which consisted of 17 multiple-choice questions. Fisher's exact test and Cochran-Mantel-Haenszel test were used to compare survey responses between cardiologists and general internists. ResultsA total of 65 survey responses were received (35.9% response rate). There were 13 cardiologists and 51 general internists who participated in the study. Cost (25%), renal function (21%) and CHADS (2) score (18%) were the three factors doctors considered most often to determine a patient's eligibility for dabigatran in warfarin-naive patients. On the other hand, histories of unstable international normalized ratio (37%) and missed appointments (17%) along with cost (19%) were most often considered in patients on warfarin. Cardiologists had prescribed dabigatran more often and had a significantly higher level of comfort with prescribing the drug than general internists (P=0.003; 77% vs. 27%). ConclusionsCost was the most important factor influencing doctors' decision to prescribe dabigatran. Safety and effectiveness of dabigatran as well as patient preference were additional factors influencing their decision. General internists were less comfortable with prescribing dabigatran than cardiologists.
引用
收藏
页码:938 / 943
页数:6
相关论文
共 50 条
  • [1] Factors influencing physicians' selection of dabigatran in non-valvular atrial fibrillation
    Huang, Cindy
    Siu, Michele
    Vu, Lily
    Wong, Soo
    Shin, Jaekyu
    PHARMACOTHERAPY, 2012, 32 (10): : E186 - E186
  • [2] Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation
    Lin, Shin-Yi
    Tang, Sung-Chun
    Kuo, Ching-Hua
    Tsai, Li-Kai
    Yeh, Shin-Joe
    Shen, Li-Jivan
    Jeng, Jiann-Shing
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (07) : 1154 - 1160
  • [3] Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation
    Tsuda, Keisuke
    Natori, Tatsunori
    Shimizu, Mie
    Ishigaku, Yoko
    Oi, Kiyotaka
    Narumi, Shinsuke
    Kamada, Asami
    Yoshida, Makiko
    Oura, Kazumasa
    Maeda, Tetsuya
    Terayama, Yasuo
    THROMBOSIS RESEARCH, 2020, 189 : 1 - 4
  • [4] Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation
    Tomita, Hideharu
    Araki, Takuya
    Kadokami, Toshiaki
    Yamada, Satoshi
    Nakamura, Ryo
    Imamura, Yoshihiro
    Fukuyama, Takaya
    Nagano, Daisuke
    Hashimoto, Tomoya
    Uematsu, Akiko
    Hosokawa, Kazuya
    Yamamoto, Koujirou
    Ueda, Shin-ichiro
    Ando, Shin-ichi
    THROMBOSIS RESEARCH, 2016, 145 : 100 - 106
  • [5] Lifestyle risk factors for non-valvular atrial fibrillation
    Buzea, C. A.
    Pagliani, L.
    Gregorio, T.
    Santos, M.
    Providencia, R.
    Weitz, J. I.
    Wallenhorst, C.
    Martinez, C.
    Cohen, A. T.
    EUROPEAN HEART JOURNAL, 2017, 38 : 239 - 239
  • [6] Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
    Novikova, Nina A.
    Volovchenko, Alexey N.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2016, 12 (05) : 590 - 594
  • [7] Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin
    Francis, Kevin M.
    Siu, Kimberly
    Yu, Chen
    Alvrtsyan, Hasmik
    Rao, Yajing
    Walker, David R.
    Sander, Stephen D.
    Zalesak, Martin
    Miyasato, Gavin
    Sanchez, Herman
    BLOOD, 2012, 120 (21)
  • [8] Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Rocha, Evangelista
    Ferreira, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2013, 32 (7-8) : 557 - 565
  • [9] Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation
    Zhu Zhu
    Zhu Shen
    Aiming Shi
    Cunjin Su
    Jiaojiao Mao
    Hong Tao
    Feng Xu
    Zhanhong Hu
    Jie Pan
    Heart and Vessels, 2022, 37 : 821 - 827
  • [10] Comparative Effectiveness of Dabigatran versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Alonso, Alvaro
    Chen, Lin Y.
    MacLehose, Richard F.
    Lutsey, Pamela L.
    CIRCULATION, 2013, 128 (22)